{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:37:08Z","timestamp":1794541028921,"version":"4.9.1"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.critrevonc.2022.103862","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T12:44:14Z","timestamp":1667306654000},"page":"103862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Anemia in myelofibrosis: Current and emerging treatment options"],"prefix":"10.1016","volume":"180","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103862_bib2","first-page":"1027","article-title":"Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study","volume":"91","author":"Abgrall","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2022.103862_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fendo.2019.00754","article-title":"Androgens and anemia: current trends and future prospects","volume":"10","author":"Al-Sharefi","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2022.103862_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100715","article-title":"Current and future therapies for myelofibrosis","volume":"42","author":"Asher","year":"2020","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103862_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103862_bib8","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.22","article-title":"Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations","volume":"6","author":"Barraco","year":"2016","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103862_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","article-title":"Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project","volume":"8","author":"Barraco","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2022.103862_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/TCRM.S258704","article-title":"Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate\/high-risk myelofibrosis: evidence to date","volume":"16","author":"Bassiony","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103862_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.13198","article-title":"Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group","volume":"102","author":"Birgegard","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103862_bib17","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103862_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103862_bib19","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-136138","article-title":"Characterization of INCB00928, a potent and selective ALK2 inhibitor for the treatment of anemia","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103862_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103862_bib22","unstructured":"ClinicalTrials.gov, 2015. Bethesda (MD): U.S. National Library of Medicine, Study to evaluate activity of 2 dose levels of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02426086\u3009. (Accessed 1 April 2022)."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Cris\u00e0","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103862_bib24","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/16078454.2021.2009645","article-title":"Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis","volume":"27","author":"Devos","year":"2022","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/fon-2017-0494","article-title":"Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia","volume":"14","author":"Diaz","year":"2018","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.critrevonc.2022.103862_bib28","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-140167","article-title":"KER-050, a modified ActRIIA ligand trap, alleviates cytopenia arising from multiple etiologies","volume":"136","author":"Feigenson","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-140364","article-title":"KER-050, a novel inhibitor of TGF-\u03b2 superfamily signaling, induces red blood cell production by promoting multiple stages of erythroid differentiation","volume":"136","author":"Feigenson","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103862_bib32","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137265","article-title":"Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) \u2013 updated data from the phase 2 ACE-536-MF-001 study","volume":"136","author":"Gerds","year":"2020","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103862_bib36","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103862_bib38","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"S1","key":"10.1016\/j.critrevonc.2022.103862_bib39","first-page":"EP1103","article-title":"Momelotinib dose-intensity is maintained in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients","volume":"4","author":"Gupta","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2022.103862_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.critrevonc.2022.103862_bib42","first-page":"EP1113","article-title":"Long term safety of momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients","volume":"4","author":"Harrison","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2022.103862_bib43","article-title":"Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in phase 2 study","volume":"5","author":"Harrison","year":"2021","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103862_bib44","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib45","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10428194.2015.1046866","article-title":"Long-term results of prednisone treatment for the anemia of myelofibrosis","volume":"57","author":"Hern\u00e1ndez-Boluda","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Hern\u00e1ndez-Boluda","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/genes3020320","article-title":"The role of bromodomain proteins in regulating gene expression","volume":"3","author":"Josling","year":"2012","journal-title":"Genes"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103862_bib50","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review","volume":"96","author":"Kc","year":"2017","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2022.103862_bib52","article-title":"Durable red blood cell transfusion independence in a patient with an MDS\/MPN overlap syndrome following discontinuation of iron chelation therapy","volume":"2015","author":"Kochhar","year":"2015","journal-title":"Case Rep. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib53","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","article-title":"Development of luspatercept to treat ineffective erythropoiesis","volume":"5","author":"Kubasch","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103862_bib54","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/17474086.2017.1366853","article-title":"Immunotherapy based approaches in myelofibrosis","volume":"10","author":"Masarova","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib55","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib56","first-page":"55","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients: update of MANIFEST phase 2 study","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103862_bib57","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103862_bib58","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib59","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103862_bib60","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.critrevonc.2022.103862_bib61","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib62","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib63","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2019-122506","article-title":"Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for Janus kinase inhibitor\u2013na\u00efve myelofibrosis patients treated with momelotinib compared head to head with ruxolitinib","volume":"134","author":"Mesa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103862_bib64","article-title":"Efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring RBC transfusions (INDEPENDENCE Trial)","volume":"5","author":"Mesa","year":"2021","journal-title":"HemaSphere"},{"issue":"Suppl 15","key":"10.1016\/j.critrevonc.2022.103862_bib65","article-title":"Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib","volume":"39","author":"Mesa","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000553","article-title":"Patient-reported effects of fedratinib, an oral, selective inhibitor of Janus kinase 2, on myelofibrosis-related symptoms and health-related quality of life in the randomized, placebo-controlled, phase III JAKARTA trial","volume":"5","author":"Mesa","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2022.103862_bib67","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2018.04.012","article-title":"Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia","volume":"69","author":"Mora","year":"2018","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib68","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib69","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.25644","article-title":"Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC group","volume":"95","author":"Mora","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"HemaSphere"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib71","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib72","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.17727","article-title":"Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib73","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103862_bib74","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib75","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103862_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib77","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2019-127859","article-title":"Updated results from the German Mpnsg-0212 combination trial: ruxolitinib plus pomalidomide in myelofibrosis with anemia","volume":"134","author":"Stegelmann","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib79","first-page":"2163","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory\/intolerant to JAK inhibitor: update from phase 2 MANIFEST study","volume":"136","author":"Talpaz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103862_bib82","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib83","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103862_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103862_bib85","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib86","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clinthera.2014.02.016","article-title":"Use of the Functional Assessment of Cancer Therapy\u2013anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia","volume":"36","author":"Tefferi","year":"2014","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103862_bib87","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103862_bib88","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103862_bib89","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cells10051034","article-title":"Next generation therapeutics for the treatment of myelofibrosis","volume":"10","author":"Tremblay","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103862_bib90","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000097463","article-title":"Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis","volume":"117","author":"Tsiara","year":"2007","journal-title":"Acta Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103862_bib92","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib93","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.critrevonc.2022.103862_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib","volume":"3","author":"Verstovsek","year":"2019","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103862_bib95","first-page":"56","article-title":"CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as \u201cadd-on\u201d to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103862_bib96","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol."},{"issue":"S3","key":"10.1016\/j.critrevonc.2022.103862_bib97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.HS9.0000843672.56808.41","article-title":"MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor","volume":"6","author":"Verstovsek","year":"2022","journal-title":"HemaSphere"},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103862_bib98","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103862_bib99","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0301-472X(00)00488-4","article-title":"Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors","volume":"28","author":"Zermati","year":"2000","journal-title":"Exp. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:51:17Z","timestamp":1760903477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822002864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":99,"alternative-id":["S1040842822002864"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103862","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia in myelofibrosis: Current and emerging treatment options","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103862"}}